Clinical Trials Browser

INDUSTRY × Interventional × Gefitinib × Clear all

NCT03040973 2026-04-02

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 3 FDA

Carcinoma, Non-Small-Cell Lung

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1 Active not recruiting

EGFR-mutant Non-small Cell Lung Cancer

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

674 enrolled 21 charts 2 FDA

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT03787992 2025-04-11

Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer （FLAG）

Phase 3 Active not recruiting

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer

NCT03944772 2025-01-30

ORCHARD

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT02588261 2024-12-10

SOLAR

Phase 3 Terminated

530 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT04248829 2024-12-03

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Phase 3 Active not recruiting

393 enrolled 13 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT03866499 2024-08-07

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Phase 3 Active not recruiting

NSCLC

NCT04143607 2024-06-14

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

452 enrolled 35 charts 2 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03599518 2023-02-08

DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Phase 1 Terminated

20 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT03849768 2023-01-20

A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients

Phase 3 Unknown

429 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT01982955 2022-11-08

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Phase 1/2 Completed

88 enrolled 45 charts

Carcinoma, Non-Small-Cell Lung

NCT02039674 2022-11-08

MK-3475-021

Phase 1/2 Completed

267 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT03758287 2022-06-22

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02088112 2022-04-04

MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT01610336 2021-04-08

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Phase 2 Completed

161 enrolled 32 charts

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04390984 2021-01-11

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Phase 1 Unknown

NSCLC

NCT01544179 2020-09-25

IMPRESS

Phase 3 Completed

265 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung

NCT02374645 2020-04-24

A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT01466660 2020-04-07

LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung

Phase 2 Completed

319 enrolled 19 charts

Lung Neoplasms

NCT04239833 2020-01-27

A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03529084 2019-11-22

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Completed

NSCLC

NCT01469000 2019-09-10

A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

195 enrolled 17 charts

Carcinoma, Non-Small-Cell Lung

NCT02179671 2019-08-02

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Phase 2 Completed

32 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03856697 2019-02-27

Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation

Phase 3 Unknown

Advanced Non-small Cell Lung Cancer

NCT03381430 2017-12-22

Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR

Phase NA Unknown

Lung Neoplasms

NCT03264794 2017-08-29

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

Phase 4 Unknown

Carcinoma, Non-Small-Cell Lung

NCT01203917 2017-01-02

IFUM

Phase 4 Completed

1,060 enrolled 14 charts

Caucasian Patients With EGFR Mutation Positive Advanced NSCLC

NCT02906163 2016-09-19

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT00357734 2016-08-30

Iressa Follow-up Trial

Phase 3 Completed

14 enrolled 10 charts

Breast Neoplasms, Lung Neoplasms

NCT00059722 2016-08-24

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT00259064 2016-06-02

INSTEP

Phase 2/3 Completed

NSCLC

NCT01530334 2016-02-23

ICARUS

Phase 2 Completed

61 enrolled 11 charts

Lung Neoplasms

NCT00770588 2016-02-08

INFORM

Phase 4 Completed

296 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00162318 2015-10-28

A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Phase 1 Completed

Carcinoma, Non-Small-Cell Lung

NCT00229697 2015-10-05

Phase II Metastatic ER+/PgR+ Nolvadex +/- Iressa Study

Phase 2 Completed

Breast Neoplasms

NCT01017874 2015-07-08

A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

Phase 3 Completed

236 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung

NCT01602289 2015-06-08

A Study of LY2875358 in Japanese Participants With Advanced Cancer

Phase 1 Completed

LymphoidThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma

NCT01039948 2015-04-08

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Phase 1/2 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT00077025 2014-07-16

Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT01040780 2014-02-14

ICOGEN

Phase 3 Completed

399 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00322452 2013-11-07

IPASS

Phase 3 Completed

1,329 enrolled 25 charts

Carcinoma, Non-Small-Cell Lung

NCT00536107 2013-10-01

Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 4 Terminated

14 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT00265070 2013-02-05

Trial of Iressa in Prostate Cancer Patients

Phase 2 Completed

Prostatic Neoplasms

NCT00090675 2013-01-29

IMAC/Herbst

Phase 3 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT00034879 2013-01-04

Iressa Expanded Access Program (EAP)

Phase 3 Completed

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms